ReviewFrontiers in nephrology2024
Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches.
Review in Frontiers in nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Prediction of Acute Kidney Injury in Oncology: From Clinical Risk Scores to AI-Enabled Precision Onco-Nephrology.Cancers · 2026Review
- Aloesin mitigates cisplatin-induced nephrotoxicity by suppressing NF-κB-mediated oxidative stress and modulating Bax/Bcl-2/caspase pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Quercetin and hesperidin attenuate cyclophosphamide-induced renal injury in rats.Journal of molecular histology · 2026Article
- Ten tips for kidney biopsy in cancer patients.Clinical kidney journal · 2026Review
- The endothelium response to kidney injury.Nature reviews. Nephrology · 2026Review
- Postoperative complications in patients with chemotherapy-induced acute myeloid leukemia (Review).Oncology letters · 2026Review
- The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.Nature reviews. Nephrology · 2026Review
- Pioglitazone Attenuates Sepsis-Associated Acute Kidney Injury by Modulating TLR-4/NF-κB Signaling and Improving Survival and Renal Function.Journal of clinical medicine · 2026Article
- The global epidemiology of acute kidney injury: challenges and opportunities.Nature reviews. Nephrology · 2026Review
- Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma.NPJ digital medicine · 2026Article
- Naringenin-functionalized polyester nanoparticles improve oral urolithin A delivery and protect against cisplatin-induced kidney injury via heme oxygenase-1 activation and mitochondrial quality control.The Journal of pharmacology and experimental therapeutics · 2026Article
- Article
- Mitochondrial Dysfunction in Acute Kidney Injury: Intersections Between Chemotherapy and Novel Cancer Immunotherapies.Biomolecules · 2026Review
- Toward Optimized Platinum Therapy: A Risk Prediction Model for Toxicity Based on Platinum Accumulation and Its Impact on Treatment Outcomes.Drug design, development and therapy · 2026Article
- Preoperative cardiovascular evaluation in patients with cancer.Frontiers in cardiovascular medicine · 2026Review
- An AOP-guidedNAM journal · 2026Article
- Comparative safety signals of carboplatin and cisplatin in lung cancer: a pharmacovigilance study based on FAERS.Frontiers in medicine · 2026Article
- Increased serum albumin corrected anion gap levels are associated with poor prognosis in sepsis-induced coagulopathy patients.PloS one · 2026Article
- Angiotensin receptor blocker ameliorates the development of tubulointerstitial injury and fibrosis associated with tubular proteinuria observed in subclinical diabetic kidney disease.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite significant advancements in oncology, conventional chemotherapy remains the primary treatment for diverse malignancies. Acute kidney injury (AKI) stands out as one of the most prevalent and severe adverse effects associated with these cytotoxic agents. While platinum compounds are well-known for their nephrotoxic potential, other drugs including antimetabolites, alkylating agents, and antitumor antibiotics are also associated. The onset of AKI poses substantial risks, including heightened morbidity and mortality rates, prolonged hospital stays, treatment interruptions, and the need for renal replacement therapy, all of which impede optimal patient care. Various proactive measures, such as aggressive hydration and diuresis, have been identified as potential strategies to mitigate AKI; however, preventing its occurrence during chemotherapy remains challenging. Additionally, several factors, including intravascular volume depletion, sepsis, exposure to other nephrotoxic agents, tumor lysis syndrome, and direct damage from cancer's pathophysiology, frequently contribute to or exacerbate kidney injury. This article aims to comprehensively review the epidemiology, mechanisms of injury, diagnosis, treatment options, and prevention strategies for AKI induced by conventional chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.